Orale Enzymtherapie bei chronischer Hepatitis C -- eine retrospektive Analyse
Standard
Orale Enzymtherapie bei chronischer Hepatitis C -- eine retrospektive Analyse. / Huber, Roman; Futter, Isabel; Goedl, Roland; Rostock, Matthias; Lüdtke, Rainer.
in: FORSCH KOMP KLAS NAT, Jahrgang 12, Nr. 3, 06.2005, S. 144-7.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Orale Enzymtherapie bei chronischer Hepatitis C -- eine retrospektive Analyse
AU - Huber, Roman
AU - Futter, Isabel
AU - Goedl, Roland
AU - Rostock, Matthias
AU - Lüdtke, Rainer
PY - 2005/6
Y1 - 2005/6
N2 - BACKGROUND AND OBJECTIVE: Data from a randomized trial in hepatitis C infected Egyptian patients suggest that the oral intake of the enzyme preparation Phlogenzym results in a significant reduction of aminotransferase levels and is equally effective to the therapy with interferon alpha. In our study, we investigated whether comparable effects can be found in daily practice in German patients.PATIENTS AND METHODS: We retrospectively evaluated the aminotransferase levels of all patients with chronic hepatitis C who were treated with Phlogenzym at a dose of 6 tablets/day in our outpatient department between 1998 and 2003. Inclusion criteria for the study were treatment duration >3 weeks and elevated alanine-aminotransferase (ALT)levels 6 months prior to and at the beginning of the treatment with Phlogenzym. Liver cirrhosis Child B or C, interferon therapy within the last 3 months before treatment with Phlogenzym and alcohol intake >30 g/day were exclusion criteria.RESULTS: 22 patients were included into the analyses. The mean duration of treatment with Phlogenzym was 77 +/- 41 days. ALT, aspartate-aminotransferase (AST) and gamma glutamyl transpeptidase (GGT) levels did not change significantly during treatment. Fitting a generalized linear model, we estimated that a hypothetical patient who started with a baseline value of 50 U/I after 90 days of treatment ends up in an ALT level of 52 U/I (95%-CI:27-77 U/I), an AST level of 51 U/I (35-67 U/I) and a GGT level of 42 U/I (22-61 U/I). 5 out of 22 patients had to stop treatment because of side effects.CONCLUSION: 6 tablets Phlogenzym per day do not seem to reduce permanently elevated aminotransferases in patients with chronic hepatitis C.
AB - BACKGROUND AND OBJECTIVE: Data from a randomized trial in hepatitis C infected Egyptian patients suggest that the oral intake of the enzyme preparation Phlogenzym results in a significant reduction of aminotransferase levels and is equally effective to the therapy with interferon alpha. In our study, we investigated whether comparable effects can be found in daily practice in German patients.PATIENTS AND METHODS: We retrospectively evaluated the aminotransferase levels of all patients with chronic hepatitis C who were treated with Phlogenzym at a dose of 6 tablets/day in our outpatient department between 1998 and 2003. Inclusion criteria for the study were treatment duration >3 weeks and elevated alanine-aminotransferase (ALT)levels 6 months prior to and at the beginning of the treatment with Phlogenzym. Liver cirrhosis Child B or C, interferon therapy within the last 3 months before treatment with Phlogenzym and alcohol intake >30 g/day were exclusion criteria.RESULTS: 22 patients were included into the analyses. The mean duration of treatment with Phlogenzym was 77 +/- 41 days. ALT, aspartate-aminotransferase (AST) and gamma glutamyl transpeptidase (GGT) levels did not change significantly during treatment. Fitting a generalized linear model, we estimated that a hypothetical patient who started with a baseline value of 50 U/I after 90 days of treatment ends up in an ALT level of 52 U/I (95%-CI:27-77 U/I), an AST level of 51 U/I (35-67 U/I) and a GGT level of 42 U/I (22-61 U/I). 5 out of 22 patients had to stop treatment because of side effects.CONCLUSION: 6 tablets Phlogenzym per day do not seem to reduce permanently elevated aminotransferases in patients with chronic hepatitis C.
KW - Administration, Oral
KW - Aspartate Aminotransferases/blood
KW - Bromelains/administration & dosage
KW - Complementary Therapies
KW - Drug Combinations
KW - Hepatitis C/blood
KW - Humans
KW - Retrospective Studies
KW - Rutin/administration & dosage
KW - Trypsin/administration & dosage
KW - gamma-Glutamyltransferase/blood
U2 - 10.1159/000082479
DO - 10.1159/000082479
M3 - SCORING: Zeitschriftenaufsatz
C2 - 15985778
VL - 12
SP - 144
EP - 147
IS - 3
ER -